70% of medicines given to children have never been studied in pediatric populations. Children who need treatments represent a relatively small population. This alone presents unique challenges for pediatric drug development. Since the 1990s, authorities around the world have worked to solve these issues, enacting legislations to encourage pediatric drug development plans—but there is still more to do. This two-part paper discusses the role global collaboration will play in bringing life-changing drugs to children who need them most. Download to read Part Two or click here to read Part One.
Explore related content and topics
Page
Brandon Early, Vice President for Project Delivery
We measure our HQ with actions, experiences, and intentions. Nowhere is that more evident that in the stories of our subject matter experts. We want…
Blog
PRA Health Sciences' 2nd Annual Celebration of World Children’s Day
Children and young adults across the globe are largely underrepresented in clinical research. While legal actions such as the Research to Accelerate…
White Paper
The Impact Of Contraceptive Requirements On Pediatric Clinical Trials
Contraceptive requirements applied to women of child-bearing potential participating in clinical trials also apply to children participating in…